Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 5,560 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Active, not recruiting Phase 3 Interventional

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

NCT05644561
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Phase 3 Interventional Results available

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)

NCT02579759
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease Type 1A
Interventions
PXT3003 dose 1, PXT3003 dose 2, placebo
Drug
Lead sponsor
Pharnext S.C.A.
Other
Eligibility
16 Years to 65 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Los Angeles, California • New Britain, Connecticut • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Phase 2 Interventional Results available

Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria

NCT00558467
View directory record Official record
Conditions
Tourette Syndrome
Interventions
pramipexole immediate release (IR), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
14
States / cities
Bradenton, Florida • Tampa, Florida • Columbus, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Not applicable Interventional

The Aging Brain ANSWERS Program

NCT03397667
View directory record Official record
Conditions
Traumatic Brain Injury, Alzheimer Disease, Veterans, Family Caregivers, Caregiver Burden, Quality of Life
Interventions
ABC ANSWERS, Control
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 90 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 17, 2026, 11:20 AM EDT
Recruiting No phase listed Observational

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

NCT06566170
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Usual Care
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Phase 2 Interventional

Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease

NCT00324454
View directory record Official record
Conditions
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Interventions
Levetiracetam
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 17, 2026, 11:20 AM EDT
Terminated Phase 4 Interventional Results available

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

NCT03661983
View directory record Official record
Conditions
Tourette's Disorder (TD)
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Anaheim, California • Riverside, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 17, 2026, 11:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ACR-2316 in Specific Advanced Solid Tumors

NCT06667141
View directory record Official record
Conditions
Specific Advanced Solid Tumors
Interventions
ACR-2316
Drug
Lead sponsor
Acrivon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Beverly Hills, California • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Not applicable Interventional Results available

Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers

NCT04948866
View directory record Official record
Conditions
Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal, Dementia, Mixed, Dementia Alzheimers, Alzheimer Disease, Dementia Severe
Interventions
ADRD-PC Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
55 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 17, 2026, 11:20 AM EDT
Not listed No phase listed Observational

Subthalamic Nucleus Deep Brain Stimulation in Speech Study

NCT05493670
View directory record Official record
Conditions
Parkinson Disease, Dysarthria
Interventions
Not listed
Lead sponsor
Jeremy Greenlee
Other
Eligibility
21 Years to 84 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Phase 4 Interventional Results available

Anti-Diabetic Medications to Fight PD and LBD

NCT06263673
View directory record Official record
Conditions
Lewy Body Dementia, Parkinson Disease
Interventions
Sitagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 17, 2026, 11:20 AM EDT
Recruiting Not applicable Interventional

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

NCT05724173
View directory record Official record
Conditions
Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Interventions
BrainGate Neural Interface System
Device
Lead sponsor
Leigh R. Hochberg, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Phase 4 Interventional

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

NCT03840837
View directory record Official record
Conditions
Parkinson Disease, Parkinson Disease Dementia
Interventions
Rivastigmine transdermal patch
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 17, 2026, 11:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease

NCT03938870
View directory record Official record
Conditions
Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders, Dementia, Mental Disorders, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies
Interventions
L-Leucine 13C6
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Phase 2 Interventional Results available

Rapalogues for Autism Phenotype in TSC: A Feasibility Study

NCT01929642
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Self-injury, Autism
Interventions
Sirolimus, Everolimus
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
2 Years to 30 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

NCT02459886
View directory record Official record
Conditions
Parkinson's Disease, Healthy
Interventions
BIIB054, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Phase 2 Interventional Results available

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

NCT02292186
View directory record Official record
Conditions
TTR-mediated Amyloidosis
Interventions
Revusiran (ALN-TTRSC)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 17, 2026, 11:20 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies
Interventions
[18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose
Drug
Lead sponsor
Daniel Claassen
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 11:20 AM EDT
Terminated Not applicable Interventional Results available

Intravenous Versus Inhalational Anesthesia in Parkinson's Disease

NCT00615472
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Isoflurane, Remifentanil, Propofol
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 17, 2026, 11:20 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

NCT03896295
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
M281
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 17, 2026, 11:20 AM EDT
Terminated Phase 2 Interventional Results available

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

NCT05744401
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AL002
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 17, 2026, 11:20 AM EDT
Recruiting Not applicable Interventional

Blood Flow Restriction for Optimizing Balance in Parkinson's Disease

NCT06508801
View directory record Official record
Conditions
Parkinson's Disease and Parkinsonism
Interventions
Blood flow restriction training, Instability Resistance Training
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 17, 2026, 11:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A BCT Intervention for an Hourly Activity Habit Among Caregivers for Persons With AD/ADRD

NCT06801912
View directory record Official record
Conditions
Sedentary Behavior
Interventions
Behavior Change Technique Package
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 17, 2026, 11:20 AM EDT
Active, not recruiting Phase 1 Interventional

Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)

NCT05377281
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Peripheral Nerve Tissue Implantation
Procedure
Lead sponsor
Craig van Horne, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 17, 2026, 11:20 AM EDT